New Delhi, March 29: Patients and healthcare providers will see a shift in the cost of essential medical supplies as the National Pharmaceutical Pricing Authority implements new ceiling prices starting April 1. The revisions target Meropenem, a broad-spectrum carbapenem antibiotic, alongside various intravenous injections used daily in clinical settings.
The price hike is pegged to the Wholesale Price Index for 2025 over 2024. While the increase for Meropenem is less than one percent, the cumulative effect is expected to influence bulk procurement by hospitals and healthcare facilities. Meropenem is frequently reserved for patients with complicated urinary tract infections or those who are immunocompromised.
An NPPA notification declared that the revision applies to Meropenem injections in dual chamber bags produced by Gufic Biosciences Limited. The 500 milligram dose was previously capped at Rs 845.94 but will now sit at Rs 851.43. Similarly, the 1,000 milligram dose will rise from Rs 1,114.72 to Rs 1,121.96.
The government maintains this price framework to keep life-saving hospital medicines financially accessible, according to officials. They affirmed that the move balances the need for affordable care with the economic realities of inflation.
Intravenous fluids are also included in the update. The price for glucose with sodium chloride injections has been set at Rs 102.34 for 1,000 ml packs and Rs 87.58 for 500 ml packs. These orders primarily affect scheduled formulations in non-glass containers manufactured by companies such as Baxter India, B Braun Medical, and Fresenius Kabi.
The regulatory body maintained that any manufacturer whose existing maximum retail price is below the old ceiling may adjust their prices upward following the established formula. However, strict penalties remain for those who exceed the new caps, as the government continues to monitor compliance across the pharmaceutical sector.
